ArticleClinical, cosmetic and investigational dermatology2026
Oral Ivarmacitinib for Stable Vitiligo: Preliminary Observations from a Three-Patient Case Series.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is an acquired autoimmune depigmenting disorder characterized by the loss of functional melanocytes. Patients with stable vitiligo may still experience slow repigmentation, marked inter-lesional variability, and limited responses to conventional therapies. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is involved in the local immune-inflammatory response in vitiligo, and the highly selective JAK1 inhibitor ivarmacitinib may therefore warrant further investigation. Case Description: This case series describes the 12-week clinical observations of three patients with stable vitiligo treated with oral ivarmacitinib. The patients included one male and two females, aged 12 to 50 years, with disease durations ranging from 9 to 36 months. The clinical subtypes included two cases of non-segmental generalized vitiligo and one case of non-segmental localized vitiligo. Two patients received ivarmacitinib 4 mg once daily, and one patient received 4 mg every other day. After 12 weeks of treatment, all three patients showed improvement in skin lesions compared with baseline. A total of 53 lesions were evaluated: 39 lesions (73.58%) showed complete or near-complete repigmentation, 12 lesions (22.64%) showed marked repigmentation, and 2 lesions (3.77%) showed moderate repigmentation; no lesions showed no response. Treatment response varied by anatomical site. Repigmentation was more pronounced on the face, neck, trunk, and extremities, whereas the response was slower on the hands and more limited on the elbows. VASI scores decreased from baseline in all three patients. No significant drug-related adverse reactions were observed during treatment. Conclusion: This three-patient case series provides preliminary 12-week observational data on the use of oral ivarmacitinib for stable vitiligo. Owing to the small sample size, lack of a control group, inconsistent dosing regimens, and short follow-up period, these findings should be interpreted as descriptive clinical observations only and do not establish efficacy or long-term safety. Further validation in studies with larger sample sizes, standardized assessments, and prospective controlled designs is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.